Metabolomics in Hyperuricemia and Gout
Gout, Urate, and Crystal Deposition Disease · 2023
DOI: 10.3390/gucdd1010006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gout, Urate, and Crystal Deposition Disease, 2023. Verfasst von Rui Li und 3 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Urate is one of the key metabolites of purine metabolism, and the overproduction of urate in the liver or decreased excretion in the kidney in humans may lead to elevated levels of urate in the circulation, termed hyperuricemia (HU). The formation of monosodium urate (MSU) crystals in the joint or surrounding tissues may trigger inflammatory responses and gout attacks, which is the most common inflammatory arthritis. In addition to gout, HU has also been associated with many other metabolic diseases, such as cardiovascular disease, obesity, diabetes, fatty liver diseases, kidney diseases, hypertension, and various cancers. Overwhelming evidence indicates that HU and gout lead to systematic metabolic alterations underlying these metabolic disorders. As one of the most powerful omics techniques, metabolomics systematically analyzes all small-molecule metabolites in a biological system that directly reflect the physiological and pathological conditions. In recent years, metabolomics has been increasingly employed in clinical and experimental research in HU and gout. Emerging studies have developed predictive models to differentiate HU from gout based on metabolomics and machine-learning algorithms. In this review, we systematically summarize recent advances in metabolomic research in gout and HU in animal and human clinical studies. A comprehensive understanding of systemic metabolic changes caused by HU and gout may provide unprecedented insights into the pathological mechanisms in HU, gout, and related metabolic diseases, which may have a profound impact on the prevention, diagnosis, and treatment of HU and gout.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Li, R., Liang, N., Tao, Y., & Yin, H. (2023). Metabolomics in Hyperuricemia and Gout. Gout, Urate, and Crystal Deposition Disease. https://doi.org/10.3390/gucdd1010006
Vancouver
Li R, Liang N, Tao Y, Yin H. Metabolomics in Hyperuricemia and Gout. Gout, Urate, and Crystal Deposition Disease. 2023. doi:10.3390/gucdd1010006
BibTeX
@article{Li2023,
author = {Li, Rui and Liang, Ningning and Tao, Yongzhen and Yin, Huiyong},
title = {Metabolomics in Hyperuricemia and Gout},
journal = {Gout, Urate, and Crystal Deposition Disease},
year = {2023},
doi = {10.3390/gucdd1010006}
}
EUVIMED